Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants

Completed · Phase 1/Phase 2

Conditions studied: Graft Versus Host Disease

In brief

This is a single arm dose escalation study of recombinant human keratinocyte growth factor given to patients undergoing allogeneic bone marrow transplantation who are at high risk for graft versus host disease (GVHD).

Key facts

Study ID

NCT00056875

Run by

University of Michigan

People needed

50

Starts

2002-09-01

Expected to finish

2005-06-01

Last updated by the study team

2015-03-25

Who can join

Age: 3 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Michigan Cancer Center — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.